Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.

ABSTRACT:

Objectives

Cutaneous melanoma rates are steadily increasing. Up to 20% of patients diagnosed with AJCC Stage I/II melanomas will develop metastatic disease. To date there are no consistently reliable means to accurately identify truly high versus low-risk patient subpopulations. There is hence an urgent need for more accurate prediction of prognosis to determine appropriate clinical management. Validation of a novel prognostic test based on the immunohistochemical expression of two protein biomarkers in the epidermal microenvironment of primary melanomas was undertaken; loss of these biomarkers had previously been shown to be associated with a higher risk of recurrence or metastasis. A parallel qualitative study exploring secondary care health professional and patient views of the

SUBMITTER: Lecouturier J 

PROVIDER: S-EPMC8979436 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature